Mesothelin: a new target for immunotherapy - PubMed (original) (raw)
Review
Mesothelin: a new target for immunotherapy
Raffit Hassan et al. Clin Cancer Res. 2004.
Abstract
Mesothelin is a differentiation antigen present on normal mesothelial cells and overexpressed in several human tumors, including mesothelioma and ovarian and pancreatic adenocarcinoma. The mesothelin gene encodes a precursor protein that is processed to yield the 40-kDa protein, mesothelin, attached to the cell membrane by a glycosylphosphatidyl inositol linkage and a 31-kDa shed fragment named megakaryocyte-potentiating factor. The biological function of mesothelin is not known. Mesothelin is a promising candidate for tumor-specific therapy, given its limited expression in normal tissues and high expression in several cancers. SS1(dsFv)PE38 is a recombinant anti-mesothelin immunotoxin that is undergoing clinical evaluation in patients with mesothelin-expressing tumors. There is evidence that mesothelin is an immunogenic protein and could be exploited as a therapeutic cancer vaccine. A soluble mesothelin variant has been identified and could be a useful tumor marker for malignant mesotheliomas.
Comment in
- Mesothelin: a new target for immunotherapy.
Shaw DR, Muminova ZE, Strong TV. Shaw DR, et al. Clin Cancer Res. 2004 Dec 15;10(24):8751; author reply 8752. doi: 10.1158/1078-0432.CCR-04-1359. Clin Cancer Res. 2004. PMID: 15623661 No abstract available.
Similar articles
- Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro.
Hassan R, Lerner MR, Benbrook D, Lightfoot SA, Brackett DJ, Wang QC, Pastan I. Hassan R, et al. Clin Cancer Res. 2002 Nov;8(11):3520-6. Clin Cancer Res. 2002. PMID: 12429643 - Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma.
Inami K, Kajino K, Abe M, Hagiwara Y, Maeda M, Suyama M, Watanabe S, Hino O. Inami K, et al. Oncol Rep. 2008 Dec;20(6):1375-80. Oncol Rep. 2008. PMID: 19020717 - Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
Hassan R, Thomas A, Alewine C, Le DT, Jaffee EM, Pastan I. Hassan R, et al. J Clin Oncol. 2016 Dec;34(34):4171-4179. doi: 10.1200/JCO.2016.68.3672. Epub 2016 Oct 31. J Clin Oncol. 2016. PMID: 27863199 Free PMC article. Review. - Mesothelin targeted cancer immunotherapy.
Hassan R, Ho M. Hassan R, et al. Eur J Cancer. 2008 Jan;44(1):46-53. doi: 10.1016/j.ejca.2007.08.028. Epub 2007 Oct 22. Eur J Cancer. 2008. PMID: 17945478 Free PMC article. Review.
Cited by
- Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy.
Malik S, Sikander M, Bell N, Zubieta D, Bell MC, Yallapu MM, Chauhan SC. Malik S, et al. J Ovarian Res. 2024 Aug 8;17(1):161. doi: 10.1186/s13048-024-01485-2. J Ovarian Res. 2024. PMID: 39118097 Free PMC article. Review. - CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer.
Tarannum M, Dinh K, Vergara J, Birch G, Abdulhamid YZ, Kaplan IE, Ay O, Maia A, Beaver O, Sheffer M, Shapiro R, Ali AK, Dong H, Ham JD, Bobilev E, James S, Cameron AB, Nguyen QD, Ganapathy S, Chayawatto C, Koreth J, Paweletz CP, Gokhale PC, Barbie DA, Matulonis UA, Soiffer RJ, Ritz J, Porter RL, Chen J, Romee R. Tarannum M, et al. Sci Adv. 2024 Jul 12;10(28):eadn0881. doi: 10.1126/sciadv.adn0881. Epub 2024 Jul 12. Sci Adv. 2024. PMID: 38996027 Free PMC article. - T cell-redirecting antibody for treatment of solid tumors via targeting mesothelin.
Liu JJ, Pan ZD, Yue YL, Wang SS, Chen J, Jiang H, Zhang BH, Wu MY, Yuan YS, Bian YL, Yin HY, Wang L, Li JY, Gilly J, Xie YQ, Zhu JW. Liu JJ, et al. Acta Pharmacol Sin. 2024 Oct;45(10):2186-2198. doi: 10.1038/s41401-024-01316-6. Epub 2024 Jun 10. Acta Pharmacol Sin. 2024. PMID: 38858494 - The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review.
Satapathy BP, Sheoran P, Yadav R, Chettri D, Sonowal D, Dash CP, Dhaka P, Uttam V, Yadav R, Jain M, Jain A. Satapathy BP, et al. Front Immunol. 2024 May 10;15:1389971. doi: 10.3389/fimmu.2024.1389971. eCollection 2024. Front Immunol. 2024. PMID: 38799440 Free PMC article. - Emerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma.
Yun KM, Bazhenova L. Yun KM, et al. Cancers (Basel). 2024 Mar 22;16(7):1252. doi: 10.3390/cancers16071252. Cancers (Basel). 2024. PMID: 38610930 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous